{"id":"without-copadm3","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL279816","moleculeType":"Small molecule","molecularWeight":"131.39"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially long-term remission.","oneSentence":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:01.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00162656","phase":"PHASE3","title":"Treatment of Mature B-cell Lymphoma/Leukaemia","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"1996-05","conditions":"B-Cell Lymphoma","enrollment":848}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"without COPADM3","genericName":"without COPADM3","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}